STAAR Surgical Reports Third Quarter 2017 Results
MONROVIA, Calif., Nov. 8, 2017 /PRNewswire/ -- STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye today reported financial results for the third quarter ended September 29, 2017.
Third Quarter 2017 Overview
- Quarterly Net Sales of $23.5 Million Up 17% from the Prior Year Quarter
- ICL Sales Up 22% and Units Up 18% from the Prior Year Quarter
- IOL Sales Down 16% and Units Down 6% from the Prior Year Quarter
- Gross Margin at 71.8% of Sales from 74.2% of Sales in the Prior Year Quarter due to Larger Volume of Lower Margin Injector Sales
- Quarterly Net Earnings per Share of $0.03 vs. Prior Year Quarter Net Loss of ($0.04) per Share
- Cash, Cash Equivalents and Restricted Cash Ended the Quarter at $16.3 Million
- Signed New and Extended Existing Strategic Agreements with Providers in China, Korea, Europe
- Continued First-in-Man Clinical Evaluation of EVO Visian ™ Implantable Collamer Lenses with EDOF for Presbyopia Correction – EU Clinical Study to Commence in Q1 2018
"During Q3, we achieved a number of milestones for the company. We were pleased to deliver a profitable quarter with $0.03 positive earnings per share and approximately $3.1 million in positive cash flow from operations. We achieved record revenue and gross profit for the quarter while benefiting from planned expense management and a shift in marketing expense for our Experts Meeting and ESCRS to the fourth quarter. Top line results include record ICL sales and record ICL units with Canada units up 200%, China units up 76%, Japan units up 48%, Germany units up 28% and Global Distributors units up 22% over the prior year quarter. China's demand was especially strong as the third quarter encompasses the largest procedure volume of the year. As we have expanded our business substantially in China, the largest refractive surgery market globally, we now will be planning for greater revenue in Q3 in future years than in previous years," said Caren Mason, President and CEO.
"Our first-in-man clinical trial for the next generation ICL with EDOF optic is nearly finished and the results continue to meet intended outcomes. We plan to begin our pivotal clinical trial during the first quarter of 2018 to evaluate the performance of an EDOF optic design to treat Presbyopia on the approved EVO Visian Implantable Collamer Lens platform. With regard to FDA remediation, we completed our internal work in the first quarter of 2017 and notified the FDA in March that we are ready for inspection," added Ms. Mason.
Financial Overview
Net sales were $23.5 million for the third quarter of 2017, up 17% compared to $20.1 million reported in the prior year quarter. The sales increase was driven by ICL revenue and unit growth of 22% and 18%, respectively, and strong injector part sales. Sales of IOLs decreased 16% compared to the prior year quarter.
Gross profit margin for the third quarter of 2017, was 71.8% compared to the prior year period of 74.2%. The decrease in gross margin for the quarter is due to unfavorable product mix due to increased sales of low margin injector parts, increased inventory provisions due to timing, and an increase in ICL unit costs, partially offset by an increased sales mix of Toric ICLs.
Operating expenses for the quarter were $15.8 million compared to the prior year quarter of $16.6 million. The decrease in operating expenses for the quarter was due to planned expense management and the timing of our Experts Meeting and the ESCRS, which were held and expensed in the third quarter of 2016 versus being held and expensed in the fourth quarter of 2017.
Net income for the third quarter of 2017 was $1.2 million or approximately $0.03 per diluted share compared with a net loss of $1.8 million or $0.04 per share for the prior year quarter.
Adjusted Net Income for the third quarter of 2017 was $1.5 million or $0.04 per diluted share, compared with an Adjusted Net Loss of $0.9 million or $0.02 per share for the prior year quarter. The reconciliation between GAAP and non-GAAP financial information is provided in the financial tables included with this release.
Cash, cash equivalents and restricted cash at September 29, 2017 totaled $16.3 million, compared to $14.1 million at the end of the fourth quarter of 2016 and $14.4 million at the end of the third quarter of 2016. Continued focus on optimizing the Company's cash position through revenue growth, expense mitigation, and working capital management enabled the Company to effectively increase its cash balances.
Conference Call
The Company will host a conference call and webcast on Wednesday, November 8, 2017 at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss its financial results and operational progress. To access the conference call (Conference ID 6998378), please dial 855-765-5684 for domestic participants and 262-912-6252 for international participants. The live webcast can be accessed from the investor relations section of the STAAR website at www.staar.com.
A taped replay of the conference call (Conference ID 6998378) will be available beginning approximately one hour after the call's conclusion for seven days. This replay can be accessed by dialing 855-859-2056 for domestic callers and 404-537-3406 for international callers. An archived webcast will also be available at www.staar.com.
Use of Non-GAAP Financial Measures
This press release includes supplemental non-GAAP financial information, which STAAR believes investors will find helpful in understanding its operating performance. "Adjusted Net Income (Loss)" and "Adjusted Net Income (Loss) Per Share" exclude the following items that are included in "Net Income (Loss)" as calculated in accordance with U.S. generally accepted accounting principles ("GAAP"): gain or loss on foreign currency transactions, stock-based compensation expenses, and quality remediation expenses. Management believes that "Adjusted Net Income (Loss)" and "Adjusted Net Income (Loss) Per Share" are useful to investors in gauging the outcome of the key drivers of the business performance: the ability to increase sales revenue and our ability to increase profit margin by improving the mix of high value products while reducing the costs over which management has control. Management has excluded quality remediation expenses because their inclusion may mask underlying trends in our business performance.
Management has also excluded gains and losses on foreign currency transactions because of the significant fluctuations that can result from period to period as a result of market driven factors. Stock-based compensation expenses consist of expenses for stock options and restricted stock under the Financial Accounting Standards Board's Accounting Standards Codification (ASC) 718. In calculating Adjusted Net Income (Loss) and Adjusted Net Income (Loss) Per Share, STAAR excludes these expenses because they are non-cash expenses and because of the complexity and considerable judgment involved in calculating their values. In addition, these expenses tend to be driven by fluctuations in the price of our stock and not by the same factors that generally affect our other business expenses.
About STAAR Surgical
STAAR, which has been dedicated solely to ophthalmic surgery for over 30 years, designs, develops, manufactures and markets implantable lenses for the eye with companion delivery systems. These lenses are intended to provide visual freedom for patients, lessening or eliminating the reliance on glasses or contact lenses. All of these lenses are foldable, which permits the surgeon to insert them through a small incision. STAAR's lens used in refractive surgery is called an Implantable Collamer® Lens or "ICL," which includes the EVO Visian ICL™ product line. More than 700,000 Visian ICLs have been implanted to date. To learn more about the ICL go to: www.discovericl.com. STAAR has approximately 340 full-time equivalent employees and markets lenses in over 60 countries. Headquartered in Monrovia, CA, the company operates manufacturing facilities in Aliso Viejo, CA and Monrovia, CA. For more information, please visit the Company's website at www.staar.com.
Safe Harbor
All statements in this press release that are not statements of historical fact are forward-looking statements, including statements about any of the following: any financial projections, including those relating to the plans, strategies, and objectives of management for future operations or prospects for achieving such plans, expectations for sales, revenue, earnings, marketing and clinical initiatives, completion of remediation or other expense, or expense timing, success and timing of new or improved products, clinical trials, research and development activities, investment imperatives, and any statements of assumptions underlying any of the foregoing. Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements are set forth in the Company's Annual Report on Form 10-K for the year ended December 30, 2016 under the caption "Risk Factors," which is on file with the Securities and Exchange Commission and available in the "Investor Information" section of the company's website under the heading "SEC Filings." We disclaim any intention or obligation to update or revise any financial projections or forward-looking statement due to new information or events.
These statements are based on expectations and assumptions as of the date of this press release and are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those described in the forward-looking statements. The risks and uncertainties include the following: our limited capital resources and limited access to financing; global economic conditions; changes in currency exchange rates; the discretion of regulatory agencies to approve or reject existing, new or improved products, or to require additional actions before approval (including but not limited to FDA requirements regarding the Visian Toric ICL and/or actions related to the FDA Warning Letter and Form FDA-483s), or to take enforcement action; research and development efforts; the purchasing patterns of our distributors carrying inventory in the market; and the willingness of surgeons and patients to adopt a new or improved product and procedure. The Visian Toric ICL and the Visian ICL with CentraFLOW, now known as EVO Visian ICL, are not yet approved for sale in the United States.
| CONTACT: |
Investors & Media |
| EVC Group |
|
| Brian Moore, 310-579-6199 |
|
| Doug Sherk, 415-652-9100 |
| STAAR Surgical Company |
||||
| Consolidated Balance Sheets |
||||
| (in 000's) |
||||
| Unaudited |
||||
| September 29, |
December 30, |
|||
| ASSETS |
2017 |
2016 |
||
| Current assets: |
||||
| Cash and cash equivalents |
$ 16,133 |
$ 13,999 |
||
| Accounts receivable trade, net |
16,237 |
16,344 |
||
| Inventories, net |
13,274 |
14,825 |
||
| Insurance receivable |
7,000 |
― |
||
| Prepayments, deposits, and other current assets |
4,936 |
4,349 |
||
| Total current assets |
57,580 |
49,517 |
||
| Property, plant, and equipment, net |
10,999 |
11,790 |
||
| Intangible assets, net |
326 |
473 |
||
| Goodwill |
1,786 |
1,786 |
||
| Deferred income taxes |
1,043 |
1,105 |
||
| Other assets |
969 |
772 |
||
| Total assets |
$ 72,703 |
$ 65,443 |
||
| LIABILITIES AND STOCKHOLDERS' EQUITY |
||||
| Current liabilities: |
||||
| Line of credit |
$ 4,442 |
$ 4,283 |
||
| Accounts payable |
5,734 |
8,311 |
||
| Obligations under capital leases |
1,269 |
1,198 |
||
| Litigation settlement obligation |
7,000 |
― |
||
| Other current liabilities |
7,253 |
7,275 |
||
| Total current liabilities |
25,698 |
21,067 |
||
| Obligations under capital leases |
834 |
1,339 |
||
| Deferred income taxes |
984 |
881 |
||
| Asset retirement obligations |
203 |
195 |
||
| Deferred rent |
184 |
59 |
||
| Pension liability |
4,138 |
3,997 |
||
| Total liabilities |
32,041 |
27,538 |
||
| Stockholders' equity: |
||||
| Common stock |
412 |
407 |
||
| Additional paid-in capital |
202,148 |
197,657 |
||
| Accumulated other comprehensive loss |
(788) |
(1,050) |
||
| Accumulated deficit |
(161,110) |
(159,109) |
||
| Total stockholders' equity |
40,662 |
37,905 |
||
| Total liabilities and stockholders' equity |
$ 72,703 |
$ 65,443 |
||
| STAAR Surgical Company |
||||||||||||||||||||
| Consolidated Statements of Operations |
||||||||||||||||||||
| (In 000's except for per share data) |
||||||||||||||||||||
| Unaudited |
||||||||||||||||||||
| Three Months Ended |
Nine Months Ended |
|||||||||||||||||||
| % of |
September 29, |
% of |
September 30, |
Fav (Unfav) |
% of |
September 29, |
% of |
September 30, |
Fav (Unfav) |
|||||||||||
| Sales |
2017 |
Sales |
2016 |
Amount |
% |
Sales |
2017 |
Sales |
2016 |
Amount |
% |
|||||||||
| Net sales |
100.0% |
$ 23,473 |
100.0% |
$ 20,052 |
$ 3,421 |
17.1% |
100.0% |
$ 65,759 |
100.0% |
$ 60,295 |
$ 5,464 |
9.1% |
||||||||
| Cost of sales |
28.2% |
6,624 |
25.8% |
5,180 |
(1,444) |
-27.9% |
28.7% |
18,859 |
29.5% |
17,804 |
(1,055) |
-5.9% |
||||||||
| Gross profit |
71.8% |
16,849 |
74.2% |
14,872 |
1,977 |
13.3% |
71.3% |
46,900 |
70.5% |
42,491 |
4,409 |
10.4% |
||||||||
| Selling, general and administrative expenses: |
||||||||||||||||||||
| General and administrative |
21.1% |
4,946 |
24.9% |
4,985 |
39 |
0.8% |
22.9% |
15,065 |
30.5% |
18,378 |
3,313 |
18.0% |
||||||||
| Marketing and selling |
27.4% |
6,431 |
35.7% |
7,149 |
718 |
10.0% |
30.8% |
20,282 |
36.5% |
22,006 |
1,724 |
7.8% |
||||||||
| Research and development |
18.9% |
4,429 |
22.2% |
4,453 |
24 |
0.5% |
21.2% |
13,924 |
26.6% |
16,018 |
2,094 |
13.1% |
||||||||
| Total selling, general, and administrative expenses |
67.4% |
15,806 |
82.8% |
16,587 |
781 |
4.7% |
74.9% |
49,271 |
93.6% |
56,402 |
7,131 |
12.6% |
||||||||
| Operating income (loss) |
4.4% |
1,043 |
-8.6% |
(1,715) |
2,758 |
160.8% |
-3.6% |
(2,371) |
-23.1% |
(13,911) |
11,540 |
83.0% |
||||||||
| Other income (expense): |
||||||||||||||||||||
| Interest expense, net |
-0.1% |
(27) |
-0.1% |
(29) |
2 |
6.9% |
-0.1% |
(88) |
-0.1% |
(85) |
(3) |
-3.5% |
||||||||
| Gain (loss) on foreign currency transactions |
1.9% |
444 |
-0.1% |
(29) |
473 |
— |
1.1% |
738 |
0.0% |
13 |
725 |
— |
||||||||
| Royalty income |
0.6% |
141 |
0.7% |
134 |
7 |
5.2% |
0.6% |
400 |
0.8% |
507 |
(107) |
-21.1% |
||||||||
| Other income (expense), net |
-0.1% |
(19) |
-0.3% |
(68) |
49 |
— |
0.0% |
17 |
-0.2% |
(150) |
167 |
— |
||||||||
| Total other income, net |
2.3% |
539 |
0.2% |
8 |
531 |
— |
1.6% |
1,067 |
0.5% |
285 |
782 |
274.4% |
||||||||
| Income (loss) before provision (benefit) for income taxes |
6.7% |
1,582 |
-8.4% |
(1,707) |
3,289 |
192.7% |
-2.0% |
(1,304) |
-22.6% |
(13,626) |
12,322 |
90.4% |
||||||||
| Provision (benefit) for income taxes |
1.7% |
409 |
0.4% |
71 |
(338) |
— |
1.1% |
697 |
-2.8% |
(1,664) |
2,361 |
— |
||||||||
| Net income (loss) |
5.0% |
$ 1,173 |
-8.8% |
$ (1,778) |
$ 2,951 |
166.0% |
-3.1% |
$ (2,001) |
-19.8% |
$ (11,962) |
$ 9,961 |
83.3% |
||||||||
| Net income (loss) per share - basic |
$ 0.03 |
$ (0.04) |
$ (0.05) |
$ (0.30) |
||||||||||||||||
| Net income (loss) per share - diluted |
$ 0.03 |
$ (0.04) |
$ (0.05) |
$ (0.30) |
||||||||||||||||
| Weighted average shares outstanding - basic |
41,110 |
40,486 |
40,939 |
40,227 |
||||||||||||||||
| Weighted average shares outstanding - diluted |
42,104 |
40,486 |
40,939 |
40,227 |
||||||||||||||||
| STAAR Surgical Company |
|||||||||
| Consolidated Statements of Cash Flows |
|||||||||
| (in 000's) |
|||||||||
| Unaudited |
|||||||||
| Three Months Ended |
Nine Months Ended |
||||||||
| September 29, |
September 30, |
September 29, |
September 30, |
||||||
| 2017 |
2016 |
2017 |
2016 |
||||||
| Cash flows from operating activities: |
|||||||||
| Net income (loss) |
$ 1,173 |
$ (1,778) |
$ (2,001) |
$ (11,962) |
|||||
| Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities: |
|||||||||
| Depreciation of property and equipment |
796 |
696 |
2,344 |
1,933 |
|||||
| Amortization of long-lived intangibles |
56 |
60 |
166 |
171 |
|||||
| Deferred income taxes |
155 |
(4) |
164 |
(1,806) |
|||||
| Change in net pension liability |
65 |
170 |
95 |
390 |
|||||
| Stock-based compensation expense |
807 |
385 |
2,185 |
8,143 |
|||||
| Loss on disposal of property and equipment |
22 |
48 |
22 |
65 |
|||||
| Provision for sales returns and bad debts |
120 |
10 |
186 |
99 |
|||||
| Inventory provision |
478 |
197 |
1,267 |
1,379 |
|||||
| Changes in working capital: |
|||||||||
| Accounts receivable |
62 |
1,772 |
41 |
1,707 |
|||||
| Inventories |
(183) |
(209) |
725 |
222 |
|||||
| Prepayments, deposits and other current assets |
(486) |
(700) |
(764) |
(1,118) |
|||||
| Accounts payable |
(984) |
(688) |
(2,751) |
594 |
|||||
| Other current liabilities |
1,023 |
1,428 |
62 |
1,104 |
|||||
| Net cash provided by operating activities |
3,104 |
1,387 |
1,741 |
921 |
|||||
| Cash flows from investing activities: |
|||||||||
| Acquisition of property and equipment |
(345) |
(718) |
(969) |
(2,709) |
|||||
| Net cash used in investing activities |
(345) |
(718) |
(969) |
(2,709) |
|||||
| Cash flows from financing activities: |
|||||||||
| Repayment of capital lease obligations |
(323) |
(118) |
(984) |
(302) |
|||||
| Proceeds from sale-leaseback transactions |
- |
- |
- |
1,154 |
|||||
| Repurchase of employee common stock for taxes withheld |
- |
- |
(234) |
(611) |
|||||
| Proceeds from vested resricted stock and exercise of stock options |
313 |
915 |
2,276 |
1,652 |
|||||
| Net cash provided by (used in) financing activities |
(10) |
797 |
1,058 |
1,893 |
|||||
| Effect of exchange rate changes on cash, cash equivalents and restricted cash |
(54) |
130 |
305 |
777 |
|||||
| Increase in cash, cash equivalents and restricted cash |
2,695 |
1,596 |
2,135 |
882 |
|||||
| Cash, cash equivalents and restricted cash, at beginning of the period |
13,558 |
12,807 |
14,118 |
13,521 |
|||||
| Cash, cash equivalents and restricted cash, at end of the period |
$ 16,253 |
$ 14,403 |
$ 16,253 |
$ 14,403 |
|||||
| STAAR Surgical Company |
|||||||||||||
| Global Sales |
|||||||||||||
| (in 000's) |
|||||||||||||
| Unaudited |
|||||||||||||
| Three Months Ended |
Nine Months Ended |
||||||||||||
| September 29, |
September 30, |
% Change |
September 29, |
September 30, |
% Change |
||||||||
| Sales by Region |
2017 |
2016 |
Fav (Unfav) |
2017 |
2016 |
Fav (Unfav) |
|||||||
| North America |
9.3% |
$ 2,192 |
12.5% |
$ 2,502 |
-12.4% |
10.3% |
$ 6,786 |
12.8% |
$ 7,726 |
-12.2% |
|||
| Europe, Middle East, Africa, Latin America |
27.4% |
6,441 |
29.8% |
5,985 |
7.6% |
30.5% |
20,033 |
31.1% |
18,764 |
6.8% |
|||
| Asia Pacific |
63.3% |
14,840 |
57.7% |
11,565 |
28.3% |
59.2% |
38,940 |
56.1% |
33,805 |
15.2% |
|||
| Total Sales |
100.0% |
$ 23,473 |
100.0% |
$ 20,052 |
17.1% |
100.0% |
$ 65,759 |
100.0% |
$ 60,295 |
9.1% |
|||
| Product Sales |
|||||||||||||
| ICLs |
77.2% |
$ 18,110 |
73.8% |
$ 14,801 |
22.4% |
75.6% |
$ 49,698 |
72.0% |
$ 43,389 |
14.5% |
|||
| IOLs |
16.6% |
3,892 |
23.2% |
4,649 |
-16.3% |
19.6% |
12,875 |
24.5% |
14,783 |
-12.9% |
|||
| Other |
6.2% |
1,471 |
3.0% |
602 |
144.4% |
4.8% |
3,186 |
3.5% |
2,123 |
50.1% |
|||
| Total Sales |
100.0% |
$ 23,473 |
100.0% |
$ 20,052 |
17.1% |
100.0% |
$ 65,759 |
100.0% |
$ 60,295 |
9.1% |
|||
| STAAR Surgical Company |
||||||
| Reconciliation of Non-GAAP Financial Measure |
||||||
| (in 000's) |
||||||
| Unaudited |
||||||
| Three Months Ended |
Nine Months Ended |
|||||
| September 29, |
September 30, |
September 29, |
September 30, |
|||
| 2017 |
2016 |
2017 |
2016 |
|||
| Net income (loss) - (as reported) |
$ 1,173 |
$ (1,778) |
$ (2,001) |
$ (11,962) |
||
| Less: |
||||||
| Foreign currency impact |
(444) |
29 |
(738) |
(13) |
||
| Stock-based compensation expense |
807 |
385 |
2,185 |
8,143 |
||
| Quality remediation expense |
- |
485 |
210 |
1,484 |
||
| Net income (loss) - (adjusted) |
$ 1,536 |
$ (879) |
$ (344) |
$ (2,348) |
||
| Net income (loss) per share, basic - (as reported) |
$ 0.03 |
$ (0.04) |
$ (0.05) |
$ (0.30) |
||
| Foreign currency impact |
(0.01) |
0.00 |
(0.02) |
(0.00) |
||
| Stock-based compensation expense |
$ 0.02 |
0.01 |
0.05 |
0.20 |
||
| Quality remediation expense |
- |
0.01 |
0.01 |
0.04 |
||
| Net income (loss) per share, basic - (adjusted) |
$ 0.04 |
$ (0.02) |
$ (0.01) |
$ (0.06) |
||
| Net income (loss) per share, diluted - (as reported) |
$ 0.03 |
$ (0.04) |
$ (0.05) |
$ (0.30) |
||
| Foreign currency impact |
(0.01) |
0.00 |
(0.02) |
(0.00) |
||
| Stock-based compensation expense |
0.02 |
0.01 |
0.05 |
0.20 |
||
| Quality remediation expense |
- |
0.01 |
0.01 |
0.04 |
||
| Net income (loss) per share, diluted - (adjusted) |
$ 0.04 |
$ (0.02) |
$ (0.01) |
$ (0.06) |
||
| Weighted average shares outstanding - Basic |
41,110 |
40,486 |
40,939 |
40,227 |
||
| Weighted average shares outstanding - Diluted |
42,104 |
40,486 |
40,939 |
40,227 |
||
| Note: Net income (loss) per share (adjusted), basic and diluted, may not add due to rounding |
SOURCE STAAR Surgical Company
Related Links
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article